文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

拔管后呼吸衰竭使用补救性无创通气的临床结局

Use of rescue noninvasive ventilation for post-extubation respiratory failure.
PubMed 文献 · Crit Care · 2025-11-04
一句话结论拔管后呼吸衰竭使用补救性无创通气失败率高(58%),但在预设再插管标准下与直接再插管相比ICU死亡率更低(校正OR=0.31),医院死亡率相似。

该研究为一项比较拔管后低氧血症患者使用高流量氧疗与文丘里面罩氧疗的随机试验的事后分析,纳入494例拔管患者中147例发生拔管后呼吸衰竭者(中位发生时间37小时),其中83例(57%)接受补救性无创通气,64例(43%)直接再插管。补救性无创通气失败率为58%,低氧性呼吸衰竭与高碳酸血症和/或呼吸窘迫患者的失败率无差异(60% vs 56%,p=0.82)。在加权队列中,与直接再插管相比,补救性无创通气与更低的ICU死亡率相关(校正OR=0.31,95%CI 0.12-0.82,p=0.019),医院死亡率相似(校正OR=1.01,95%CI 0.43-2.33,p=0.99)。作者结论认为补救性无创通气失败率高,但在明确再插管标准下使用时似乎不明确增加医院死亡率,需随机试验重新评估其疗效。

要点

  • 拔管后呼吸衰竭患者中,补救性无创通气失败率为58%,低氧性呼吸衰竭与高碳酸血症和/或呼吸窘迫患者失败率无差异(60% vs 56%,p=0.82)。
  • 加权队列中,补救性无创通气与直接再插管相比,ICU死亡率更低(校正OR=0.31,95%CI 0.12-0.82,p=0.019)。
  • 补救性无创通气与直接再插管的医院死亡率相似(校正OR=1.01,95%CI 0.43-2.33,p=0.99)。
  • 贝叶斯分析显示,在所有先验下补救性无创通气降低ICU死亡率的后验概率>90%。
  • 补救性无创通气不增加医院死亡率的后验概率在无信息先验下为44%,怀疑先验下为47%,悲观先验下为39%。

适用人群与场景

  • 拔管后低氧血症患者,来自比较高流量氧疗与文丘里面罩氧疗的随机试验。
  • 纳入拔管后按预设标准发生呼吸衰竭者,中位发生时间为拔管后37小时(IQR 13-85)。

诊断标准与关键阈值

  • 拔管后呼吸衰竭按预设标准定义。
  • 无创通气期间再插管标准为预设标准。

处置流程与药物剂量

  • 补救性无创通气由医生决定实施,再插管标准为预设标准。

研究设计与关键结果

  • 研究类型:随机试验的事后分析;样本量:494例拔管患者中147例发生呼吸衰竭,83例(57%)接受补救性无创通气,64例(43%)直接再插管。
  • 补救性无创通气失败率为58%。
  • 低氧性呼吸衰竭与高碳酸血症和/或呼吸窘迫患者无创通气失败率无差异(60% vs 56%,p=0.82)。
  • 加权队列中,补救性无创通气与直接再插管相比,ICU死亡率校正OR=0.31(95%CI 0.12-0.82,p=0.019)。
  • 加权队列中,补救性无创通气与直接再插管相比,医院死亡率校正OR=1.01(95%CI 0.43-2.33,p=0.99)。
  • 补救性无创通气降低ICU死亡率的后验概率在所有先验下>90%。
  • 补救性无创通气不增加医院死亡率的后验概率:无信息先验44%,怀疑先验47%,悲观先验39%。

证据类型、等级与局限

  • 证据类型:随机试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为补救性无创通气失败率高,但在明确再插管标准下使用时似乎不明确增加医院死亡率。
  • 作者认为需要随机试验重新评估补救性无创通气对拔管后呼吸衰竭的疗效。

指南或共识出处

  • 临床试验注册:clinicaltrials.gov(NCT02107183),注册日期2014年4月8日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Robust evidence supports the use of preemptive non-invasive ventilation (NIV) after extubation in selected high-risk patient cohorts. In contrast, current guidelines discourage the use of NIV as a rescue therapy for respiratory failure that develops later after extubation, based on earlier studies indicating a potential increase in hospital mortality due to delayed reintubation. Nonetheless, NIV continues to be employed in this setting. We conducted a post-hoc analysis of a randomized trial to assess the clinical outcomes of rescue NIV for post-extubation respiratory failure.

METHODS: In this post-hoc analysis of a randomized trial comparing high-flow with Venturi mask oxygen in hypoxemic patients after extubation, we included those who developed post-extubation respiratory failure according to prespecified criteria; patients who received rescue NIV per physician's decision were compared to those who received direct re-intubation. Criteria for re-intubation during NIV were prespecified. Odds ratio after inverse probability of treatment weighting and posterior probabilities by Bayesian regression are reported.

RESULTS: Among 494 extubated patients, 147 developed respiratory failure while receiving oxygen therapy, occurring at a median of 37 h [IQR 13-85] after extubation: 83 (57%) were treated with rescue NIV and 64 (43%) received immediate re-intubation. The rate of NIV failure was 58%, without differences between patients with hypoxemic respiratory failure and those with hypercapnia and/or respiratory distress (60% vs. 56%, p = 0.82). In the weighted cohort, the use of rescue NIV, compared to direct re-intubation, was associated with lower intensive care unit mortality (adjusted odds ratio = 0.31 [95%CI: 0.12-0.82], p = 0.019) and similar hospital mortality (adjusted odds ratio = 1.01 [95%CI: 0.43-2.33], p = 0.99). The posterior probability that NIV reduced intensive care unit mortality was > 90% across all priors. The posterior probability that NIV did not increase hospital mortality was 44% under a noninformative prior, 47% under a skeptical prior, and 39% under a pessimistic prior.

CONCLUSION: Rescue NIV for post-extubation respiratory failure is associated with high failure rates; however, when applied with well-defined criteria for reintubation, it does not appear to be clearly associated with increases in hospital mortality. A randomized trial to re-evaluate the efficacy of rescue NIV for post-extubation respiratory failure is warranted.

CLINICAL TRIAL REGISTRATION: Registered at clinicaltrials.gov (NCT02107183) on April 8th, 2014.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Grieco DL, Jaber S, Zakynthinos S, et al. Use of rescue noninvasive ventilation for post-extubation respiratory failure. Crit Care. 2025. PMID: 41188988. doi:10.1186/s13054-025-05689-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。